Nitto Avecia

Company

Last mentioned: Mar 24, 2026

Timeline

Mar 24, 2026
Analyst Sentiment Review

Major firms maintain ratings, citing steady execution of the strategic pivot.
Mar 12, 2026
2026 Guidance Issued

Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Mar 11, 2026
Q4 2025 Earnings Release

Codexis reports significant beats on both top and bottom lines.

Stories mentioning Nitto Avecia 1

pharma Neutral

Codexis Sustains Analyst Confidence Following Q4 Beat and 2026 Revenue Guidance

Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.

Mar 24, 2026 2 sources